Everything below concerns albumin binding. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-12-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
Semaglutide is a synthetic peptide that acts as an agonist at the glucagon-like peptide-1 receptor. It is a structural analogue of human GLP-1(7-37), modified to resist enzymatic degradation by dipeptidyl peptidase-4. The peptide backbone contains alpha-aminoisobutyric acid at position 8, a substitution that stabilises the helix and slows cleavage. A fatty diacid side chain attached through a linker at lysine 34 promotes binding to serum albumin, which extends the circulating half-life. These two modifications together allow less frequent administration than native GLP-1 requires.
Activation of the GLP-1 receptor couples to Gs signalling and raises intracellular cyclic AMP in pancreatic beta cells. The resulting insulin release depends on prevailing glucose concentrations, so the effect is greater when glucose is elevated. Receptor engagement also suppresses glucagon secretion and slows gastric emptying, which flattens post-meal glucose excursions. In the central nervous system, signalling in hypothalamic and brainstem regions is associated with reduced appetite and lower energy intake. Studies continue to examine effects on cardiac, renal and hepatic endpoints; whether those benefits are independent of weight change remains an open question.
Clinical development of this compound followed earlier short-acting GLP-1 analogues that required frequent injection. Once-weekly subcutaneous formulations entered use after 2017, and an oral formulation using a permeation enhancer later became available. The oral version pairs the peptide with sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, a carrier that improves uptake across the gastric epithelium. Interest has expanded from glycaemic control into weight management and metabolic liver disease. Regulatory status and approved indications differ between countries, and the product remains subject to ongoing safety monitoring.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide, GLP-1 receptor agonist | Not a small molecule |
| Backbone substitutions | Non-natural residue at position 8, arginine at position 34 | Slows enzymatic cleavage |
| Side chain | C18 fatty diacid with PEG linker | Enables albumin binding |
| Approximate molecular mass | 4114 Da | Varies slightly with salt form |
| Reported half-life | About one week | Longer than native GLP-1 by orders of magnitude |
As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.
Storage guidance for the finished injectable product distinguishes the unused state from the in-use state. Before first use, pens are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and never frozen, since freezing can disrupt the peptide or the device. After first use, label instructions in several markets permit storage at room temperature up to about 30 degrees Celsius for a limited number of days. Solid research-grade material is normally held at or below minus 20 degrees Celsius, often with desiccant, and allowed to equilibrate before opening.
Quantification and purity assessment rely on separation methods coupled to optical or mass detection. Reversed-phase high-performance liquid chromatography resolves the intact peptide from related impurities and is the standard assay technique. Size-exclusion chromatography measures aggregates, while ion-exchange chromatography separates charge variants produced by deamidation. Mass spectrometry confirms identity and detects mass shifts of a few daltons. In biological matrices, liquid chromatography with tandem mass spectrometry is often used because immunoassays can cross-react with endogenous GLP-1 or with circulating fragments.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
He criticised Israel for its attacks on government and civilians and expressed gratitude for American, Arab, and Turkish mediators for de-escalating the conflict and said that "the Israeli entity resorted to a wide-scale targeting of civilian and government facilities", adding that it led to a "significant complication of the situation and pushed matters to a large-scale escalation". On 16 July 2025, US Secretary of State Marco Rubio stated that the United States was making progress for a ceasefire agreement including Israel, saying "We hope to see some real progress to end what you've been seeing over the last couple of hours", as he addressed reporters at the Oval Office. According to a Turkish security source, Turkish intelligence officers held talks with Syrian Druze leaders for securing the ceasefire. İbrahim Kalın, the director of the Turkish National Intelligence Organization, also held discussions with his Israeli, American and Syrian counterparts, as well as Ahmed al-Sharaa. A joint "Gulf-Arab-Turkish" statement reaffirmed their support for Syrian integrity and "welcomed" al-Sharaa's commitment to hold to account fighters who took part in "abuses". According to the spiritual leadership of the Druze in Syria, the agreement signed for a ceasefire from 19 July included a number of key steps intended to bring about calm and an end to the conflicts in the area.
In February 2021, federal prosecutors accused Holmes and other executives of destroying evidence in Theranos's final days in business. The specific evidence in question is the history of internal testing, including accuracy and failure rates of Theranos's blood-testing systems. On January 3, 2022, Holmes was found guilty of four counts of wire fraud and one count of conspiracy to commit wire fraud. She was sentenced in November 2022 to 11 years and 3 months in prison. On May 30, 2023, Holmes began serving her sentence at Federal Prison Camp, Bryan in Bryan, Texas. Balwani's trial began in March 2022 and he was convicted of 12 counts of fraud in July 2022. In December he was sentenced to 12 years and 11 months in prison and three years of probation.
=== Long-Term Potentiation === Long-Term Potentiation (LTP) is the increase in sensitivity of homosynapses that augment the synapse's strength and signal transduction. In the context of OIH, LTP has been shown to contribute to hyperalgesia by hypersensitizing areas of nociceptive processing, particularly at synapses between C fibers and the spinal cord dorsal horn. Studies that attempted to link LTP and hyperalgesia have found that drugs able to block LTP (ketamine and minocycline) also decrease hyperalgesia. In addition, LTP and OIH both utilize NMDA receptors and their activity can be reduced by NMDA receptor antagonists (i.e. ketamine).
Sources: en.wikipedia.org
== Brain and nervous system == Astrocytoma Anaplastic astrocytoma Brainstem glioma Choroid plexus carcinoma Craniopharyngioma Ependymoma Ganglioneuroma Glioblastoma Glioma Hemangioblastoma Medulloblastoma Meningioma Neuroblastoma Neurofibroma Oligodendroglioma Paraganglioma Pineal astrocytoma Pineocytoma Pineoblastoma Pituitary adenoma Pilocytic astrocytoma Primary central nervous system lymphoma Primitive neuroectodermal tumor Schwannoma Visual pathway and hypothalamic glioma
Paradoxical effects: In some cases, paradoxical effects can occur with benzodiazepines, such as increased hostility, aggression, angry outbursts, and psychomotor agitation. These effects are seen more commonly with lorazepam than with other benzodiazepines. Paradoxical effects are more likely to occur with higher doses, in people with pre-existing personality disorders and those with a psychiatric illness. Frustrating stimuli may trigger such reactions, though the drug may have been prescribed to help the person cope with such stress and frustration in the first place. As paradoxical effects appear to be dose-related, they usually subside on dose reduction or on complete withdrawal of lorazepam. Suicidality: Benzodiazepines are associated with an increased risk of suicide, possibly due to disinhibition. Higher dosages appear to confer greater risk. Amnesic effects: Among benzodiazepines, lorazepam has relatively strong amnesic effects, but people soon develop tolerance to this with regular use. An initial total daily lorazepam dose that does not exceed 2 mg may help avoid amnesia (or excess sedation) being a problem. This also applies to use for night sedation. Five participants in a sleep study were prescribed lorazepam 4 mg at night, and the next evening, three subjects unexpectedly volunteered memory gaps for parts of that day, an effect that subsided completely after two to three days' use. Amnesic effects cannot be estimated from the degree of sedation present, since the two effects are unrelated.
Alfonso Vidal also said that at his final meeting with Agent Poll, Poll told him that he could manipulate the public into believing anything, and even convince the country that Alfonso Vidal was a thief, as "...money can go missing anytime." Alfonso Vidal also stated that he firmly believed that Grand Treasurer Airán Cervera was either in the employment of the Ministry of the Interior or the National Revolutionary Police Force. He said that Grand Treasurer Airán Cervera could not be trusted.
Sources: en.wikipedia.org
==== Maya Belizeans ==== The Maya are thought to have been in the Yucatán region and thus in Belize since the second millennium BCE. Classical Maya culture collapsed between the 7th and 9th centuries CE which left vast areas of Belize without population. Many Mayas also died in internal conflict and several hundred years later by catching disease from invading Europeans. Three Maya groups inhabit the country:
In addition, after a time the silk will lose its stickiness and thus become inefficient at capturing prey. It is common for spiders to eat their own web daily to recoup some of the energy used in spinning. Through ingestion and digestion, the silk proteins are thus recycled. Due to the incredible strength of spider silk, scientists are currently studying it in the hope of creating a super-tough material with similar properties.
The substrates of this enzyme are dihydrobiopterin (specifically the isomer (6R)-L-erythro-6,7-dihydrobiopterin), reduced nicotinamide adenine dinucleotide (NADH), and two protons. Its products are tetrahydropteridine and oxidised NAD+. Nicotinamide adenine dinucleotide phosphate can be used as an alternative cofactor. The enzyme participates in folate biosynthesis. In the human genome, the enzyme is encoded by the QDPR gene.
One interpretation of the data is that polypeptide monomers are often aligned in the multimer in such a way that mutant polypeptides defective at nearby sites in the genetic map tend to form a mixed multimer that functions poorly, whereas mutant polypeptides defective at distant sites tend to form a mixed multimer that functions more effectively. Direct interaction of two nascent proteins emerging from nearby ribosomes appears to be a general mechanism for homo-oligomer (multimer) formation. Hundreds of protein oligomers were identified that assemble in human cells by such an interaction. The most prevalent form of interaction is between the N-terminal regions of the interacting proteins. Dimer formation appears to be able to occur independently of dedicated assembly machines. The intermolecular forces likely responsible for self-recognition and multimer formation were discussed by Jehle.
Sources: en.wikipedia.org
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.
Albumin binding keeps a large fraction of the compound in a slowly released reservoir within the bloodstream. Plasma levels decline gradually rather than falling sharply after each administration. That profile supports dosing intervals measured in days instead of hours.
The active peptide sequence is the same in both formats. The oral version adds an absorption enhancer that is not present in the injected solution. Differences in excipients and formulation affect uptake rather than the identity of the active molecule.
It belongs to the incretin mimetic class and acts as a long-acting glucagon-like peptide-1 receptor agonist. The class includes several peptides with different half-lives and routes of administration.